Biotech Values

[DewDiligence]

MRK’s V116 (adult pneumococcal vaccine) has 6/17/24 PDUFA date—(with FDA priority review):

https://www.businesswire.com/news/home/20231219406441/en

V116 is 21-valent—i.e. it contains 13 of the 20 serotypes in PFE’s Prevnar-20 and 8 new serotypes. By simple arithmetic, V116 lacks 7 of the serotypes in Prevnar-20, but MRK contends that those 7 serotypes are less influential than the 8 new serotypes.

PFE currently has a >90% share of the adult market for pneumococcal vaccines, but V116 will presumably get MRK back in the game. See #msg-172452293 and #msg-166441188 for related info.

Note: V116 is a distinct product from MRK’s Vaxneuvance (a/k/a V114).